[{"data":1,"prerenderedAt":183},["ShallowReactive",2],{"drug-daunorubicin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":35,"contraindications":80,"warnings":90,"renal":98,"monitoring":99,"interactions":100,"review":101,"examples":104,"atc":117,"iran":119,"links":135,"populations":152,"usApproval":178},"daunorubicin",1,{"fa":7,"en":8},"داونوروبیسین","Daunorubicin","antineoplastic-immunomodulating",{"fa":11,"en":12},"آنتراسایکلین","Anthracycline",[14],{"name":15,"market":16},"Cerubidine","US",[18,19,20,7],"cerubidine","daunomycin","داونومایسین",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"inj-5","injection","iv","5 mg\u002FmL (20 mg\u002F4 mL, 50 mg\u002F10 mL)",{"amount":28,"unit":29,"perVolumeMl":5},5,"mg",[16],[32],{"source":33,"section":34},"fda-daunorubicin","How Supplied",[36,63],{"id":37,"disease":38,"label":39,"population":42,"type":48,"unit":29,"dose":49,"refs":51,"durationDays":54,"notes":56},"aml","acute-myeloid-leukemia",{"fa":40,"en":41},"القای AML بزرگسال زیر ۶۰ سال — ۴۵ mg\u002Fm²\u002Fروز وریدی روز ۱ تا ۳ (دوره‌های بعد روز ۱ و ۲) با سیتارابین","AML induction, adults under 60 — 45 mg\u002Fm²\u002Fday IV on days 1–3 (later courses days 1–2) with cytarabine",{"minAge":43,"maxAge":46},{"value":44,"unit":45},18,"year",{"value":47,"unit":45},60,"bsa",{"perM2PerDay":50,"dividedDoses":5},45,[52],{"source":33,"section":53},"Dosage and Administration",{"min":55,"max":55},3,[57],{"text":58,"refs":61},{"fa":59,"en":60},"فقط زیر نظر پزشک متخصص شیمی‌درمانی و در مرکز مجهز. عدد ماشین‌حساب = mg\u002Fm² برچسب × سطح بدن (Mosteller)؛ پروتکل، فاصله دوره‌ها، تنظیم بر اساس CBC و عملکرد کلیه\u002Fکبد با تیم انکولوژی.","Only under an oncologist in an equipped centre. Calculator = label mg\u002Fm² × BSA (Mosteller); protocol, cycle interval and adjustment for CBC and renal\u002Fhepatic function rest with the oncology team.",[62],{"source":33,"section":53},{"id":64,"disease":38,"label":65,"population":68,"type":48,"unit":29,"dose":70,"refs":72,"durationDays":74,"notes":75},"aml-60",{"fa":66,"en":67},"القای AML ۶۰ سال و بالاتر — ۳۰ mg\u002Fm²\u002Fروز روز ۱ تا ۳ با سیتارابین","AML induction, 60 years and over — 30 mg\u002Fm²\u002Fday on days 1–3 with cytarabine",{"minAge":69},{"value":47,"unit":45},{"perM2PerDay":71,"dividedDoses":5},30,[73],{"source":33,"section":53},{"min":55,"max":55},[76],{"text":77,"refs":78},{"fa":59,"en":60},[79],{"source":33,"section":53},[81],{"id":82,"severity":83,"text":84,"refs":87},"hyper","block",{"fa":85,"en":86},"حساسیت به داونوروبیسین.","Hypersensitivity to daunorubicin.",[88],{"source":33,"section":89},"Contraindications",[91],{"text":92,"refs":95},{"fa":93,"en":94},"سمیت قلبی با دوز تجمعی بالای ۴۰۰ تا ۵۵۰ mg\u002Fm² در بزرگسال (۳۰۰ mg\u002Fm² در کودک بالای ۲ سال، ۱۰ mg\u002Fkg زیر ۲ سال)؛ سرکوب شدید مغز استخوان؛ فقط توسط پزشک باتجربه در لوسمی.","Cardiotoxicity above cumulative 400–550 mg\u002Fm² in adults (300 mg\u002Fm² in children over 2, 10 mg\u002Fkg under 2); severe myelosuppression; only by physicians experienced in leukaemia therapy.",[96],{"source":33,"section":97},"Warnings",[],[],[],{"status":102,"reviewer":103,"date":103},"unverified",null,[105,112],{"regimen":37,"formulation":23,"input":106,"expect":110},{"ageYears":107,"weightKg":108,"heightCm":109},55,80,180,{"perDose":111,"mlPerDose":44},90,{"regimen":64,"formulation":23,"input":113,"expect":115},{"ageYears":114,"weightKg":108,"heightCm":109},65,{"perDose":47,"mlPerDose":116},12,[118],"L01DB02",{"status":120,"forms":121,"refs":130},"registered",[122,126],{"code":123,"en":124,"fa":125},"00384","DAUNORUBICIN HCL 20MG VIAL","ویال داونوروبیسین هیدروکلراید ۲۰ میلی‌گرم",{"code":127,"en":128,"fa":129},"52506","DAUNORUBICIN (AS HYDROCHLORIDE) INJECTION, SOLUTION PARENTERAL 2 mg\u002F1mL 10 mL","محلول تزریقی داونوروبیسین (معادل هیدروکلراید) ۲ میلی‌گرم \u002F ۱ میلی‌لیتر ۱۰ میلی‌لیتر",[131],{"source":132,"section":133,"url":134},"darooyab-generic","G-979\u002FDaunorubicin","https:\u002F\u002Fwww.darooyab.ir\u002FG-979\u002FDaunorubicin",[136,140,144,147,150],{"kind":137,"url":138,"label":139},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=208759","ANDA208759",{"kind":141,"url":142,"label":143},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=9705fa12-499e-41a3-8fb4-f6df0858b851","FDA Daunorubicin",{"kind":145,"url":146,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682289.html",{"kind":148,"url":149,"label":118},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01DB02",{"kind":151,"url":134,"label":8},"darooyab",{"pregnancy":153,"lactation":162,"pediatric":171},{"level":154,"text":155,"quote":158,"refs":159},"avoid",{"fa":156,"en":157},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Daunorubicin hydrochloride may cause fetal harm when administered to a pregnant woman.",[160],{"source":33,"section":161},"Pregnancy",{"level":163,"text":164,"quote":167,"refs":168},"caution",{"fa":165,"en":166},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from daunorubicin, mothers should be advised to discontinue nursing during daunorubicin therapy.",[169],{"source":33,"section":170},"Nursing Mothers",{"level":163,"text":172,"quote":175,"refs":176},{"fa":173,"en":174},"برچسب: در کودکان حد دوز تجمعی کمتر است (۳۰۰ mg\u002Fm² بالای ۲ سال، ۱۰ mg\u002Fkg زیر ۲ سال) — سمیت قلبی.","Label: children have lower cumulative limits (300 mg\u002Fm² over 2 years, 10 mg\u002Fkg under 2) — cardiotoxicity.","The incidence of myocardial toxicity increases after a total cumulative dose exceeding 400 to 550 mg\u002Fm 2 in adults, 300 mg\u002Fm 2 in children more than 2 years of age, or 10 mg\u002Fkg in children less than 2 years of age.",[177],{"source":33,"section":97},{"kind":179,"refs":180,"id":139},"ANDA",[181],{"source":33,"section":182},"SPL approval \u002F marketing category",1792444709798]